Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study

Yamane, Toshimi; Ishii, Kenji; Sakata, Muneyuki; Ikari, Yasuhiko; Nishio, Tomoyuki; Ishii, Kazunari; Kato, Takashi; Ito, Kengo; Senda, Michio

doi:10.1007/s00259-016-3591-2

Cited by 98 publications

(86 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is consistent with kappa values in the range 0.73–0.82 reported by Harn et al [18], who evaluated the agreement among three experienced raters in the reading of 55 florbetapir PET scans, and with the kappa values reported by Buckley et al [19], who found that most values were greater than 0.80. Yamane et al [20] found a slightly higher kappa value of 0.89 with 11 C-based Pittsburgh compound B, which may be explained by the fact that 57 normal controls were included in the test cohort of 162 patients. Patients without cognitive impairment might exhibit lower variability leading to higher kappa values than patients with various levels of cognitive impairment, as those in our cohort.…”

Section: Discussionmentioning

confidence: 99%

Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation

Bělohlávek

Jaruskova

Skopalová

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation

Bělohlávek

Jaruskova

Skopalová

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…18 F-labeled PiB (Florbetapir) was synthesized with NEPTIS ® plug-01, intravenously injected for 9 participants at an Okayama University-affiliated hospital, and 60-90 min later PET images were detected for 30 min. For two AD patients at Oita University, 11 C-PiB was injected to take PET images [9,10]. As the whole cerebellar region of interest (ROI) for reference, an average of standard uptake value (SUV) from 6 cerebral cortical areas were calculated in order to analyze positive or negative for PiB-PET (positive for more than 1, negative for 1 or less).…”

Section: Pet Imagingmentioning

confidence: 99%

“…Diagnosis of AD is usually based on clinical criteria, but may be supported by biochemical markers such as a decreased amyloid-␤ (A␤) 42 [3], and increased A␤ oligomer [4,5] and tau protein in cerebrospinal fluid (CSF) [3]. Radiological analyses are also sometimes undertaken as supportive biomarkers of AD with single photon emission computed tomography (SPECT) for evaluating cerebral blood flow [6,7] and positron emission tomography (PET) for A␤ using Pittsburgh compound B (PiB) [8][9][10] and tau [11][12][13]. However, blood samples are more feasible and plausible than CSF or radiological biomarkers for screening emerging number of potential AD and other dementias [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer’s Disease by Peptidome Technology

Abe

Shang

Shi

et al. 2020

JAD

View full text Add to dashboard Cite

Background: Because dementia is an emerging problem in the world, biochemical markers of cerebrospinal fluid (CSF) and radio-isotopic analyses are helpful for diagnosing Alzheimer's disease (AD). Although blood sample is more feasible and plausible than CSF or radiological biomarkers for screening potential AD, measurements of serum amyloid-␤ (A␤), plasma tau, and serum antibodies for A␤ 1-42 are not yet well established. Objective: We aimed to identify a new serum biomarker to detect mild cognitive impairment (MCI) and AD in comparison to cognitively healthy control by a new peptidome technology. Methods: With only 1.5 l of serum, we examined a new target plate "BLOTCHIP ® " plus a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) to discriminate control (n = 100), MCI (n = 60), and AD (n = 99). In some subjects, cognitive Mini-Mental State Examination (MMSE) were compared to positron emission tomography (PET) with Pittsburgh compound B (PiB) and the serum probability of dementia (SPD). The mother proteins of candidate serum peptides were examined in autopsied AD brains. Results: Apart from A␤ or tau, the present study discovered a new diagnostic 4-peptides-set biomarker for discriminating control, MCI, and AD with 87% of sensitivity and 65% of specificity between control and AD (* * * p < 0.001). MMSE score was well correlated to brain A␤ deposition and to SPD of AD. The mother proteins of the four peptides were upregulated for coagulation, complement, and plasticity (three proteins), and was downregulated for anti-inflammation (one protein) in AD brains.

show abstract

“…All PiB-PET images were visually interpreted and classified as positive or negative by two PiB-PET expert physicians after consultation. 13,14 Quantitative analysis of amyloid deposition was performed with the automated method. 15 We used PMOD software (PMOD Technologies, Zurich, Switzerland) for all image analysis.…”

Section: Carbon-11-labelled Pittsburgh Compound B Positron Emission Tmentioning

confidence: 99%

Effect of Feru‐guard 100M on amyloid‐beta deposition in individuals with mild cognitive impairment

2020

View full text Add to dashboard Cite

Aim: Many researchers argue that Alzheimer's disease is at least partly caused by deposition of amyloid beta (Aβ) in the brain. Ferulic acid (FA) and Angelica archangelica (AA) are candidate agents for reducing Aβ and improving cognitive function. Feru-guard 100M is a supplement containing FA and AA extract. Using this supplement, we planned to assess the effect of FA and AA on Aβ deposition in the human brain. Methods: This was an open-label, interventional multi-institutional joint study of Kobe University and the Institute of Biomedical Research and Innovation (Kobe, Japan). Seventeen subjects diagnosed with mild cognitive impairment were divided into two groups: the intervention group (n = 10) and the control group (n = 7). The subjects in the intervention group used Feru-guard 100M every day for 48 weeks, whereas the subjects in the control group did not use the supplement. We assessed the differences between the two groups by examining Aβ deposition and brain atrophy at 48 weeks and cognitive function every 24 weeks. We used carbon-11-labelled Pittsburgh compound B (PiB) positron emission tomography to evaluate Aβ deposition. Results: There were no significant differences in Aβ deposition, brain atrophy, and cognitive function between the two groups. Specifically, differences in Aβ deposition change in seven regions of interest examined with PiB positron emission tomography, brain atrophy change in four indicators of voxel-based morphometry, and cognitive impairment measured by five psychological tests were not significantly between the two groups. Conclusion: Treatment with Feru-guard 100M, a supplement containing FA and AA extract, for 48 weeks did not reduce cortical PiB retention, which reflects Aβ deposition. It also did not suppress the aggravation of brain atrophy or decline in cognitive function.

show abstract

Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study

Cited by 98 publications

References 31 publications

Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation

Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation

A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer’s Disease by Peptidome Technology

Effect of Feru‐guard 100M on amyloid‐beta deposition in individuals with mild cognitive impairment

Contact Info

Product

Resources

About